- Home
- FWRG vs CVAC Comparison
FWRG vs CVAC Comparison
Compare FWRG & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FWRG
- CVAC
- Stock Information
- Founded
- FWRG 1983
- CVAC 2000
- Country
- FWRG United States
- CVAC Germany
- Employees
- FWRG N/A
- CVAC N/A
- Industry
- FWRG Restaurants
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- FWRG Consumer Discretionary
- CVAC Health Care
- Exchange
- FWRG Nasdaq
- CVAC Nasdaq
- Market Cap
- FWRG 1.0B
- CVAC 818.8M
- IPO Year
- FWRG 2021
- CVAC 2020
- Fundamental
- Price
- FWRG $19.59
- CVAC $3.12
- Analyst Decision
- FWRG Strong Buy
- CVAC Buy
- Analyst Count
- FWRG 10
- CVAC 2
- Target Price
- FWRG $22.80
- CVAC $10.00
- AVG Volume (30 Days)
- FWRG 731.4K
- CVAC 717.4K
- Earning Date
- FWRG 05-06-2025
- CVAC 04-10-2025
- Dividend Yield
- FWRG N/A
- CVAC N/A
- EPS Growth
- FWRG N/A
- CVAC N/A
- EPS
- FWRG 0.30
- CVAC 0.75
- Revenue
- FWRG $1,015,910,000.00
- CVAC $554,073,921.00
- Revenue This Year
- FWRG $21.47
- CVAC N/A
- Revenue Next Year
- FWRG $15.96
- CVAC $66.34
- P/E Ratio
- FWRG $65.30
- CVAC $4.19
- Revenue Growth
- FWRG 13.95
- CVAC 895.54
- 52 Week Low
- FWRG $12.90
- CVAC $2.22
- 52 Week High
- FWRG $25.98
- CVAC $5.28
- Technical
- Relative Strength Index (RSI)
- FWRG 61.63
- CVAC 53.48
- Support Level
- FWRG $15.03
- CVAC $3.05
- Resistance Level
- FWRG $17.31
- CVAC $3.02
- Average True Range (ATR)
- FWRG 1.23
- CVAC 0.19
- MACD
- FWRG 0.37
- CVAC 0.06
- Stochastic Oscillator
- FWRG 94.80
- CVAC 79.14
About FWRG First Watch Restaurant Group Inc.
First Watch Restaurant Group Inc is a daytime restaurant concept serving made-to-order breakfast, brunch, and lunch using fresh ingredients. It generates revenues from Restaurant sales and Franchise revenues.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.